Scientists are excitedly focused on retatrutide, a novel drug from Eli Lilly, as a significant step in physique loss . Distinct from many previous approaches, retatrutide is a dual -action agonist targeting equally GLP-1 and GIP, chemicals that impact appetite and blood sugar regulation . Initial c